EGCG-Caffeine Cocrystals for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Epigallocatechin gallate (EGCG) has limited bioavailability when taken orally, and existing methods to enhance its bioavailability, such as nanolipid particle generation and crystal engineering, have not been fully effective, while caffeine cocrystals with other compounds have shown potential but not with EGCG.
Innovation Solution
The development of cocrystals of EGCG and caffeine in specific molar ratios, such as 2:1, through methods like slurry-titration and vacuum filtration, which alter the physical properties and stability of both compounds, including their solubility and melting points, leading to distinct forms like Form I and Form II.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional preformulation techniques such as nanolipid particle generation and crystal engineering are used to enhance EGCG bioavailability, then bioavailability is improved, but the improvement is not fully effective
Solution Approach 1:
The patent creates cocrystals by combining EGCG with coformers (such as caffeine, benzoic acid, or salicylic acid) in specific molar ratios to form composite crystalline structures. These cocrystals exhibit enhanced bioavailability compared to pure EGCG while maintaining stability, directly resolving the contradiction by providing a more effective enhancement approach than conventional single-technique methods
Solution Approach 2:
The patent systematically varies parameters including the choice of coformer, molar ratios (e.g., 1:1, 2:1), and crystallization conditions to optimize the cocrystal structure. This parameter optimization enables achieving both high bioavailability enhancement effectiveness and stability, overcoming the limitations of conventional approaches
2Stability of the object's composition
If cocrystals are formed with specific molar ratios to alter physical properties, then solubility and stability are improved, but the crystal form complexity increases
Solution Approach 1:
The patent identifies and characterizes distinct cocrystal forms (Form I, Form II) with specific local structural characteristics, including unique x-ray diffraction patterns and melting points. Each form has optimized local properties for stability while the overall system manages complexity through systematic characterization and selection of appropriate forms for specific applications
3Reliability
If cocrystals are formed to improve bioavailability, then pharmacokinetic properties are enhanced, but the manufacturing process complexity increases
Solution Approach 1:
The patent establishes predetermined cocrystal formulations with optimized molar ratios and characterized physical properties before clinical application. By pre-characterizing multiple cocrystal forms and selecting the most suitable one for manufacturing, the approach simplifies the manufacturing process while ensuring enhanced bioavailability, rather than attempting to optimize during production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cocrystals of EGCG and caffeine demonstrate improved bioavailability and stability, with Form I and Form II exhibiting unique x-ray diffraction patterns and melting points, enhancing their pharmacokinetic properties and potential therapeutic benefits.
Implementation Method 1
The development of cocrystals of EGCG and caffeine in specific molar ratios, such as 2:1, through methods like slurry-titration and vacuum filtration, which alter the physical properties and stability of both compounds
Implementation Method 2
Form I and Form II exhibiting unique x-ray diffraction patterns and melting points
Data Source
AI summary
Described herein are cocrystals of epigallocatechin gallate (ECGC) and caffeine, compositions comprising such cocrystals, methods of making such cocrystals, and methods of improving animal or human health by treating with such cocrystals. In particular, Form I and Form II of a 1:2 (epigallocatechin gallate to caffeine) cocrystal are described.